Table 2 Treatment outcome
FOLFOX-4 (n = 29) | Topotecan (n = 26) | |
|---|---|---|
Median follow-up, months (range) | 45 (1–45) | 57 (1–57) |
Median PFS, months (95% CI) | 2.8 (1.7–4.9) | 2.8 (1.8–4.9) |
Median OS, months (95% CI) | 6.2 (2.4–14.6) | 10.4 (4.9–19.5) |
Tumor response, n (%) | ||
CR | 1 (3.5) | 1 (3.8) |
PR | 5 (17.2) | 1 (3.8) |
SD | 8 (27.6) | 6 (23.1) |
PD | 15 (51.7) | 18 (69.3) |
Ca125 response*, n (%) | 11 (44.0) | 5 (26.3) |
Number of patients receiving new treatment after progression, n (%) | 16 (57.1) | 17 (65.4) |